Despite the fact that nearly half of all patients with non-small cell lung cancer (NSCLC) present with stage III disease, this is the treatment setting with the least well-established standards. Generally treated with curative intent, patients with stage III disease usually receive more than one of the three main therapeutic approaches to lung cancer-surgery, radiation, and chemotherapy. In addition, the staging system encompasses a remarkably heterogeneous range of tumor burden and location within the rubric of stage III. Consequently, an individualized approach is often invoked to address particular concerns for resectability, toxicity, and patient and physician preferences. For patients with locally advanced NSCLC, therapeutic outcomes have improved overall for this population over the past few decades. While there exists a range of acceptable standard approaches to the treatment of stage III NSCLC, this review will describe several conclusions that have emerged and how they evolved.

中文翻译：

---

局部晚期非小细胞肺癌治疗的当前标准和正在进行的争论。

尽管事实上所有非小细胞肺癌（NSCLC）患者中有近一半患有III期疾病，但这是标准水平最低的治疗方案。通常以治愈目的治疗，III期疾病患者通常会接受肺癌，外科手术，放射线和化学疗法的三种主要治疗方法中的一种以上。此外，分期系统涵盖了肿瘤负荷的显着异质范围和III期分期内的位置。因此，通常会采用个性化方法来解决对可切除性，毒性以及患者和医生偏好的特殊关注。对于局部晚期NSCLC的患者，过去几十年来，该人群的治疗效果总体上得到了改善。